| Diabetes Mellitus

Afrezza - (Insulin Human) Inhalation Powder vs Novolog 70/30

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.
Deep comparison between: Afrezza vs Novolog Mix 70/30 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsNovolog Mix 70/30 has a higher rate of injection site reactions vs Afrezza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Novolog Mix 70/30 but not Afrezza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Afrezza
Novolog Mix 70/30
At A Glance
Oral inhalation
At each meal
Rapid-acting insulin
SC injection
Twice daily
Insulin analog
Indications
  • Diabetes Mellitus
  • Diabetes Mellitus
Dosing
Diabetes Mellitus Insulin-naive patients: 4 units inhaled at the beginning of each meal; patients switching from subcutaneous mealtime insulin convert per table (up to 3 units -> 4 units, 4-5 units -> 8 units, 6-7 units -> 12 units, >=8 units -> 16 units); adjust dose based on metabolic needs, blood glucose monitoring, and glycemic control goal.
Diabetes Mellitus Inject subcutaneously in the abdominal region, buttocks, thigh, or upper arm twice daily within 15 minutes before meal initiation (or after meal initiation for type 2 patients); individualize dose based on metabolic needs, blood glucose monitoring results, and glycemic control goal.
Contraindications
  • Episodes of hypoglycemia
  • Chronic lung disease such as asthma or COPD due to risk of acute bronchospasm
  • Previous severe hypersensitivity reaction to any regular human insulin product or any inactive ingredient in AFREZZA
  • Episodes of hypoglycemia
  • Hypersensitivity to Novolog Mix 70/30 or one of its excipients
Adverse Reactions
Most common (>=2%) Cough, throat pain or irritation, headache, diarrhea, productive cough, fatigue, nausea
Serious Acute bronchospasm, hypoglycemia, decline in pulmonary function, lung cancer, diabetic ketoacidosis, hypersensitivity reactions
Postmarketing Bronchospasm
Most common (>=5%) Hypoglycemia, headache, influenza-like symptoms, dyspepsia, back pain, diarrhea, pharyngitis, rhinitis, skeletal pain, upper respiratory tract infection, neuropathy, abdominal pain
Serious Severe hypoglycemia requiring assistance or parenteral glucose/glucagon, anaphylaxis, lipodystrophy, localized cutaneous amyloidosis
Postmarketing Localized cutaneous amyloidosis at injection site, hyperglycemia with repeated injections into areas of amyloidosis, hypoglycemia with sudden change to unaffected injection site, medication errors due to accidental substitution
Pharmacology
Insulin lowers blood glucose in adult patients with diabetes mellitus by stimulating peripheral glucose uptake by skeletal muscle and fat and by inhibiting hepatic glucose production; it also inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.
Biphasic insulin analog consisting of 70% insulin aspart protamine (prolonged absorption) and 30% soluble insulin aspart (rapid absorption); lowers blood glucose by stimulating peripheral glucose uptake in skeletal muscle and fat and by inhibiting hepatic glucose production.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Afrezza
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
View full coverage details ›
Novolog Mix 70/30
  • Covered on 5 commercial plans
  • PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
View full coverage details ›
UnitedHealthcare
Afrezza
  • Covered on 4 commercial plans
  • PA (6/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Novolog Mix 70/30
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
View full coverage details ›
Humana
Afrezza
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
View full coverage details ›
Novolog Mix 70/30
  • Covered on 0 commercial plans
  • PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
$99/momo
Afrezza Patient Direct Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Novolog Mix 70/30.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
AfrezzaView full Afrezza profile
Novolog Mix 70/30View full Novolog Mix 70/30 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.